Skip to main content

Table 2 TP53 mutations, survival and histopathological features for each case.

From: TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival

Case a BRCA1 carrier type Stage bGrade Type TTGE Exon Codon Mutation aa change Age of diagnosis cSurvival months dVital status
3453 1 3 2 ser pos 5   559+1G>A splice 53 83 1
10 1 3 3 ser pos 6 213 CGA>TGA arg>stop 65 22 3
2857 1 3 3 ser pos 6 213 CGA>TGA arg>stop 53 83 3
4 1 4 3 ser pos 6 216 GTG>ATG val>met 59 11 3
27 1 2 3 endo pos 7 237 ATG>ATA met>ile 39 61 3
8 e 1 3 3 ser pos 7 260 TCC>TCT ser>ser 49 84 3
       8 306 CGA>TGA arg>stop    
14 1 1 3 ser pos 8 267 CGG>CAG arg>gln 51 25 3
13 1 4 3 ser pos 8 273 CGT>AGT arg>ser 39 15 3
29 1 3 3 mix pos 8 273 CGT>TGT arg>cys 50 36 3
2842 1 1 4 3 ser pos 8 273 CGT>TGT arg>cys 39 35 3
21 1 3 3 ser pos 8 293 GGG>AGG gly>arg 39 21 3
26 1 3 2 ser pos   intron G>A ivs5 53 93 1
9 1 4 2 ser neg      50 39 3
11 1 3 3 ser neg      44 8 3
17 1 3 3 ser neg      47 30 3
24 1 2 4 ser neg      59 20 3
34 1 1 3 ser neg      46 120 1
30 1 1 2 ser neg      43 199 2
32 1 2 3 ser neg      48 108 1
3351 1 4 3 endo neg      44 9 3
1 2 4 3 ser pos 5 144 CAG>TAG gln>stop 41 1 3
3 2 3 3 uncl pos 6 196 CGA>TGA arg>stop 48 46 3
20 2 3 3 ser pos 6 205 TAT>TCT tyr>ser 52 36 3
28 2 4 3 ser pos 7 261 AGG>AGA arg>arg 80 12 3
7 e 2 3 3 ser pos 7 255 ATC>GTC ile>val 58 30 3
       5 141 TGC>TGT cys>cys    
12 2 1 3 ser pos 8 280 AGA>GGA arg>gly 49 134 1
15 2 3 3 ser pos   intron C>T ivs7 50 19 3
5 2 4 3 ser neg      60 45 3
18 2 2 3 endo neg      44 117 3
22 2 3 2 mix neg      47 96 3
  1. a: 1 = 1675delA and 2 = 1135insA. b: undifferentiated (4). c: all patients were followed until diseased or to 15th April, 2004. d: alive without cancer (1), alive with cancer (2), and dead by cancer (3). e: two different mutations detected in sample.